IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
Sereti I, Dunham RM, Spritzler J et al.; ACTG 5214 Study Team.
In this randomized, placebo-controlled, dose-ranging clinical trial of single-dose subcutaneous injection of interleukin-7 administered to 11 patients with HIV on highly active antiretroviral therapy, the investigators found few adverse events and a potentially favorable increase in circulating CD4+ and CD8+ cells of central memory phenotype.
» Read an expert review of this paper